Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow International Stem Cell CORP

Get SEC filing alerts via email and in your feed for International Stem Cell CORP

ISCO

International Stem Cell CORP

About International Stem Cell CORP

International Stem Cell Corporation is a biotech company specializing in pluripotent stem cell research and development. It creates proprietary human parthenogenetic stem cells for therapeutic applications, notably in neurodegenerative diseases like Parkinson’s. The company also develops research tools and consumer skin care products. Its core value lies in ethically derived, immune-matched stem cells aimed at regenerative medicine, drug discovery, and cosmetic markets.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from International Stem Cell CORP

1
1
International Stem Cell CORP International Stem Cell Corporation Reports 9% Increase in Product Sales for Q1 2026

Via official filing (AI summary) | 25 days ago | 0 comments

2
1
International Stem Cell CORP International Stem Cell Corporation Reports $9.1 Million Revenue for Fiscal Year 2025

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
International Stem Cell CORP International Stem Cell Corporation Reports Q3 2025 Financial Results with Increased Sales and Reduced Net Losses

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
International Stem Cell CORP International Stem Cell Corporation Reports Modest Sales Growth and Continued Net Loss in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
International Stem Cell CORP International Stem Cell Corporation Reports Stable Sales but Increased Net Loss in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
International Stem Cell CORP International Stem Cell Corporation Reports $9.1 Million Revenue for Fiscal Year 2024

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
International Stem Cell CORP International Stem Cell Corporation Reports Mixed Q3 Results with Revenue Growth and Increased Losses

Via official filing (AI summary) | over 1 year ago | 0 comments